| Cash Flow | 2025-09-30 | 2025-06-30 |
|---|---|---|
| Net loss | -169,793 | -86,693 |
| Stock-based compensation expense | 17,100 | 8,762 |
| Depreciation and amortization | 1,715 | 873 |
| Operating lease, right-of-use-asset amortization | 376 | 185 |
| Finance lease, right-of-use-asset amortization | 1,214 | 607 |
| Net amortization of premiums and discounts on short-term investments | 2,098 | 1,339 |
| Noncash interest expense | 829 | 415 |
| Unrealized foreign currency transaction (gains) | 284 | -591 |
| Research and development incentives receivable | -1,264 | -1,631 |
| Prepaid expenses and other current assets | -94 | -234 |
| Accounts payable | -5,165 | 3,765 |
| Accrued expenses and other current liabilities | -2,766 | -5,536 |
| Operating lease liabilities | -398 | -195 |
| Other non-current liabilities | -316 | -316 |
| Net cash used in operating activities | -158,228 | -77,016 |
| Purchases of property, plant and equipment | 4,083 | 2,740 |
| Purchase of short-term investments | 47,430 | 37,581 |
| Proceeds from sales and maturities of short-term investments | 200,730 | 105,369 |
| Net cash provided by investing activities | 149,217 | 65,048 |
| Proceeds from issuance of common stock, net of fees and offering costs | 0 | 0 |
| Proceeds from issuance of prefunded warrants to purchase common stock, net of underwriting fees and offering costs | 0 | 0 |
| Principal payment of finance lease obligation | 343 | 166 |
| Proceeds from exercise of stock options and pre-funded warrants | 509 | 8 |
| Net cash provided by financing activities | 166 | -158 |
| Effect of exchange rate changes on cash, cash equivalents and restricted cash | 26 | -1,616 |
| Net (decrease) increase in cash, cash equivalents and restricted cash | -8,819 | -13,742 |
| Cash and cash equivalents at beginning of period | 112,822 | - |
| Cash and cash equivalents at end of period | 104,003 | - |
Replimune Group, Inc. (REPL)
Replimune Group, Inc. (REPL)